Marie-Ange Demoitie

Phase 2a Trial of 0, 1, and 3 Month and 0, 7, and 28 Day Immunization Schedules of Malaria Vaccine RTS,S/AS02 in Malaria-Naive Adults at the Walter Reed Army Institute of Research (2008)

Kester, Kent E., Cummings, James F., Ockenhouse, Christian F., Nielsen, Robin, Hall, B. Ted, Gordon, Daniel M., ...

Background: Immunization with RTS,S/AS02 consistently protects some vaccinees against malaria infection in experimental challenges and in field trials. A brief immunization schedule against...

Strong Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Activity in Sydney Blood Bank Cohort Patients Infected with nef-Defective HIV Type 1

Dyer, Wayne B., Ogg, Graham S., Demoitie, Marie-Ange, Jin, Xia, Geczy, Andrew F., Rowland-Jones, Sarah L., ...

Proposals for the use of live attenuated human immunodeficiency virus (HIV) type 1 (HIV-1) as a vaccine candidate in humans have been based on the protection afforded by attenuated simian...

HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

Ortiz, Gabriel M., Nixon, Douglas F., Trkola, Alexandra, Binley, James, Jin, Xia, Bonhoeffer, Sebastian, ...

Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex...

Strong Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Activity in Sydney Blood Bank Cohort Patients Infected with nef-Defective HIV Type 1

Dyer, Wayne B., Ogg, Graham S., Demoitie, Marie-Ange, Jin, Xia, Geczy, Andrew F., Rowland-Jones, Sarah L., ...

Proposals for the use of live attenuated human immunodeficiency virus (HIV) type 1 (HIV-1) as a vaccine candidate in humans have been based on the protection afforded by attenuated simian...

HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

Ortiz, Gabriel M., Nixon, Douglas F., Trkola, Alexandra, Binley, James, Jin, Xia, Bonhoeffer, Sebastian, ...

Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex...

Murine Immune Responses to Liver-Stage Antigen 1 Protein FMP011, a Malaria Vaccine Candidate, Delivered with Adjuvant AS01B or AS02A▿

Brando, Clara, Ware, Lisa A., Freyberger, Helen, Kathcart, April, Barbosa, Arnoldo, Cayphas, Sylvie, ...

Liver-stage antigen 1 (LSA1) is expressed by Plasmodium falciparum only during the intrahepatic cell stage of the parasite's development. Immunoepidemiological studies in regions where malaria is...

Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone▿

Stewart, V. Ann, McGrath, Shannon M., Dubois, Patrice M., Pau, Maria G., Mettens, Pascal, Shott, Joseph, ...

The RTS,S/AS02A protein-based vaccine consistently demonstrates significant protection against infection with Plasmodium falciparum malaria and also against clinical malaria and severe disease in...

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

Polhemus, Mark E., Remich, Shon A., Ogutu, Bernhards R., Waitumbi, John N., Otieno, Lucas, Apollo, Stella, ...

Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

Owusu-Agyei, Seth, Ansong, Daniel, Asante, Kwaku, Kwarteng Owusu, Sandra, Owusu, Ruth, Wireko Brobby, Naana Ayiwa, ...

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon

Lell, Bertrand, Agnandji, Selidji, Von Glasenapp, Isabelle, Haertle, Sonja, Oyakhiromen, Sunny, Issifou, Saadou, ...